Dovydas Širvinskas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dovydas Širvinskas has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Sukanta Jash
Center on the Biology of Aging, Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, 225 Dyer Street, Providence, RI 02903, USA
1 shared publication
Latest Publications
- Open Access
- 2 July 2026
- Published by MDPI AG in Preprints.org
Reprogramming the Brain—iPSC Models Illuminating the Pathogenesis and Treatment of Alzheimer’s Disease and Other Dementias
Induced pluripotent stem cells (iPSCs) have revolutionized the research landscape for Alzheimer's disease (AD) and related dementias by providing human, patient-specific neuronal models for studying the genetic and phenotypic diversity of these disorders. This review aims to integrate the latest advances in iPSC-based modeling of AD and dementia across multiple levels of biological organization. After describing the principles of pluripotency, iPSC generation, and quality control (genetic integrity, pluripotency assessment, long-term stability) the review will compare 2D monolayer culture with 3D organoid-based systems regarding their ability to model amyloid-beta, tau, and neuroinflammatory aspects of AD and dementia. The development of global stem cell biobanks and large iPSC collections with genetic diversity will be highlighted as an essential tool for dissecting the complex interplay of multiple genetic risk factors, ethnicity-based differences, and genotype-phenotype correlations. The review will discuss the use of genome editing technology, such as CRISPR/Cas9, for studying the effect of specific AD risk and protective variants in neurons and glial cells, and their implications for cell type-specific roles in neurodegeneration and neuroinflammation. We will highlight the challenges and limitations of iPSCs, such as cellular immaturity, loss of aging signatures, limited vascularization, and batch-to-batch differences, while noting the latest advances in partial/direct reprogramming, biomaterials science, and AI-based phenotypic analysis. Finally, the review will cover the expanding use of iPSC-based systems for high-content screening, functional therapeutic target validation, biomarker discovery, and development, and provide an overview of the future prospects for “clinical-trials-in-a-dish” and precision medicine for AD and other dementia disorders.
- 2 July 2026
- Published by MDPI AG in Preprints.org
Open AccessReprogramming the Brain—iPSC Models Illuminating the Pathogenesis and Treatment of Alzheimer’s Disease and Other Dementias
Induced pluripotent stem cells (iPSCs) have revolutionized the research landscape for Alzheimer's disease (AD) and related dementias by providing human, patient-specific neuronal models for studying the genetic and phenotypic diversity of these disorders. This review aims to integrate the latest advances in iPSC-based modeling of AD and dementia across multiple levels of biological organization. After describing the principles of pluripotency, iPSC generation, and quality control (genetic integrity, pluripotency assessment, long-term stability) the review will compare 2D monolayer culture with 3D organoid-based systems regarding their ability to model amyloid-beta, tau, and neuroinflammatory aspects of AD and dementia. The development of global stem cell biobanks and large iPSC collections with genetic diversity will be highlighted as an essential tool for dissecting the complex interplay of multiple genetic risk factors, ethnicity-based differences, and genotype-phenotype correlations. The review will discuss the use of genome editing technology, such as CRISPR/Cas9, for studying the effect of specific AD risk and protective variants in neurons and glial cells, and their implications for cell type-specific roles in neurodegeneration and neuroinflammation. We will highlight the challenges and limitations of iPSCs, such as cellular immaturity, loss of aging signatures, limited vascularization, and batch-to-batch differences, while noting the latest advances in partial/direct reprogramming, biomaterials science, and AI-based phenotypic analysis. Finally, the review will cover the expanding use of iPSC-based systems for high-content screening, functional therapeutic target validation, biomarker discovery, and development, and provide an overview of the future prospects for “clinical-trials-in-a-dish” and precision medicine for AD and other dementia disorders.